FDA clearance creates a new use case for Tandem Diabetes Care stock

Tandem Diabetes Care (TNDM) just received US FDA clearance for its Control-IQ+ technology in pregnancies complicated by type 1 diabetes, making its t:slim X2 and Tandem Mobi systems the only automated insulin delivery options approved for this use in the country.

The FDA clearance comes after a mixed period for the stock, with a 7 day share price return of 4.24% and a 30 day share price return of 4.35%. This is set against a year to date share price decline of 9.88% and a 3 year total shareholder return decline of 40.65%, suggesting that while recent momentum has improved, long term holders have experienced meaningful volatility.

If this kind of regulatory milestone has your attention, it can be useful to see what else is happening across healthcare technology. You can broaden your search with our 35 healthcare AI stocks

With Tandem shares down 9.88% year to date but trading at what some models flag as a sizeable intrinsic discount, the real question is whether this FDA win leaves upside on the table or whether markets are already pricing in future growth.

Most Popular Narrative: 36.9% Undervalued

With Tandem Diabetes Care last closing at $19.42 against a narrative fair value of $30.76, the current price sits well below that modeled outcome, setting up a clear tension between the stock and the story behind it.

Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels, supporting future revenue growth, margin expansion, and improved earnings.

Want to see what makes that pharmacy shift so powerful in the model? The narrative leans heavily on faster earnings improvement, expanding margins, and a richer revenue mix over time.

Result: Fair Value of $30.76 (UNDERVALUED)

However, this hinges on Tandem handling tougher pump competition and successfully executing the pharmacy and PayGo rollout, while avoiding the operational or reimbursement snags analysts flag.

Next Steps

With the mix of optimism and concern running through this story, it makes sense to move quickly and weigh the full picture for yourself using our 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might suit your goals even better, so give yourself options and compare.

• Target potential mispricings by scanning a curated set of quality opportunities using the 51 high quality undervalued stocks
• Prioritise staying power and financial resilience by reviewing companies in the solid balance sheet and fundamentals stocks screener (46 results)
• Spot potential up-and-comers before they are widely followed with the screener containing 25 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.